Atezolizumab

Introduction Overview

Generic Name

atezolizumab

Brand Name

Tecentriq

Dosage Form

Intravenous infusion (IV), single-dose vial

Drug Class

Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)

Pharmacokinetics

Absorption:
Atezolizumab is a monoclonal antibody administered intravenously, resulting in complete bioavailability upon administration. It bypasses the gastrointestinal tract and avoids first-pass metabolism, ensuring direct systemic availability. The intravenous infusion is typically administered over 60 minutes initially, which may be shortened to 30 minutes if the patient tolerates the drug well. This route enables rapid achievement of therapeutic plasma concentrations necessary for optimal engagement with PD-L1 targets on tumor and immune cells.

Distribution:
After infusion, atezolizumab demonstrates a limited volume of distribution consistent with other monoclonal antibodies, primarily confined to vascular and interstitial spaces. Its distribution is influenced by the binding to programmed death-ligand 1 (PD-L1) expressed on tumor cells and immune cells within the tumor microenvironment and peripheral blood. The drug's large molecular size restricts diffusion through cellular membranes but facilitates specific binding interactions. Protein binding is not a relevant pharmacokinetic factor for monoclonal antibodies like atezolizumab. Monoclonal antibodies have complex distribution patterns, often impacted by receptor saturation and target-mediated drug disposition.

Metabolism:
Atezolizumab undergoes catabolism by proteolytic enzymes throughout the body, typical for therapeutic antibodies. This metabolism occurs via nonspecific degradation pathways within the reticuloendothelial system and is not dependent on cytochrome P450 enzymes or hepatic metabolic pathways. The proteolytic cleavage breaks atezolizumab into small peptides and amino acids, which are reutilized or eliminated. This mechanism minimizes the risk for drug–drug interactions with agents metabolized by common hepatic enzymes and supports safe co-administration with multiple chemotherapeutic agents.

Elimination:
Atezolizumab exhibits a relatively long half-life, approximately 27 days, allowing dosing intervals of two to four weeks. It is cleared primarily via proteolytic degradation rather than renal or hepatic excretion. The half-life and clearance are influenced by factors such as target-mediated drug disposition and overall patient physiology, including tumor burden and immune status. Because elimination is not renal or hepatic dependent, atezolizumab is suitable for use in patients with hepatic or renal impairment without significant dose adjustment. The long half-life enables sustained PD-L1 inhibition to maintain immune checkpoint blockade over prolonged treatment periods.

Dosage Forms

Available Dosage Forms:
Tecentriq is available as single-dose vials for intravenous infusion.
- Single-Dose Vial: 1200 mg/20 mL (concentration 60 mg/mL)
- Single-Dose Vial: 840 mg/14 mL (concentration 60 mg/mL)

Dosages for Adults and Adolescents:
- For Non-Small Cell Lung Cancer (NSCLC):
• Monotherapy dosing: 840 mg IV every 2 weeks or 1200 mg every 3 weeks or 1680 mg every 4 weeks.
• In combination with platinum-based chemotherapy (e.g., bevacizumab, paclitaxel, carboplatin): 1200 mg IV every 3 weeks for 4 to 6 cycles, then maintenance dosing as monotherapy.

- For Small Cell Lung Cancer (SCLC):
• 1200 mg IV every 3 weeks with carboplatin and etoposide for 4 cycles, then maintenance at 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks.

- Hepatocellular Carcinoma (HCC):
• 1200 mg IV every 3 weeks, administered with bevacizumab 15 mg/kg on the same day.

- Melanoma (BRAF V600 mutation-positive metastatic):
• 840 mg IV every 2 weeks combined with cobimetinib and vemurafenib oral therapies.

- Alveolar Soft Part Sarcoma (ASPS):
• Adults: 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks.
• Pediatric patients (≥2 years): 15 mg/kg (up to max 1200 mg) every 3 weeks.

Specific Patient Populations:
- Pediatric patients: Limited to alveolar soft part sarcoma treatment; dosing based on body weight with a maximum cap.
- Renal or hepatic impairment: No dose adjustment generally required due to elimination by proteolytic degradation, not hepatic metabolism.
- Patients with abnormal EGFR or ALK gene expression in NSCLC: Typically require alternative approved therapies before initiation.
- Pregnancy and lactation: Not recommended; contraindicated in pregnancy with advised contraception for at least 5 months post-treatment.

Administration Notes:
- The initial infusion is given over 60 minutes; subsequent infusions may be reduced to 30 minutes if well tolerated.
- Should be administered prior to chemotherapy or other antineoplastic agents when combined on the same day.
- Infusion is intravenous only and requires administration by healthcare professionals.
- There is a subcutaneous formulation (Tecentriq Hybreza) administered every 3 weeks but not detailed in this dataset.

Mechanism Of Action

Atezolizumab (Tecentriq) is a humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1), a cell surface protein expressed on tumor cells and tumor-infiltrating immune cells. PD-L1 binds to its receptor PD-1 located on activated T lymphocytes, delivering inhibitory signals that suppress T-cell function, allowing tumors to evade immune surveillance. By binding PD-L1, atezolizumab prevents its interaction with PD-1, effectively releasing the immune checkpoint blockade and reactivating T-cell mediated antitumor responses.

The drug selectively disrupts the PD-1/PD-L1 pathway without affecting the PD-L2 ligand, preserving certain immune regulatory functions to reduce potential autoimmune side effects. This selective blockade reinvigorates cytotoxic T lymphocytes, enhancing their proliferation, cytokine secretion, and tumor cell killing capabilities. This mechanism promotes recognition and destruction of cancerous cells by the patient's immune system, contributing to tumor regression.

Atezolizumab’s binding to PD-L1 does not induce antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) because it is engineered to minimize Fc receptor binding, reducing potential damage to normal immune cells expressing PD-L1. This is an important safety feature distinguishing it from other monoclonal antibodies.

Clinical research and trials have demonstrated that blocking the PD-1/PD-L1 axis with atezolizumab improves survival outcomes in a range of cancers, especially those exhibiting high PD-L1 expression or tumor-infiltrating immune cells indicative of an immunologically active microenvironment. Its mechanism positions it among immune checkpoint inhibitors, distinct from cytotoxic chemotherapies, with a favorable efficacy and safety profile for multiple malignancies including lung cancer, hepatocellular carcinoma, melanoma, and soft tissue sarcoma.

Pharmacological Actions

Immune checkpoint inhibition via PD-L1 binding and blockade of PD-1/PD-L1 interaction.
Enhancement of T-cell mediated immune response against tumor cells by reversing T-cell exhaustion.
Selective immune modulation avoiding complement activation and ADCC to preserve immune cell integrity.
Induction of durable antitumor immunity promoting tumor regression and prolonged survival.
Synergistic activity in combination with chemotherapy and other targeted agents to improve efficacy.
Modulation of tumor microenvironment by reversing immunosuppression.
Potential to cause immune-related adverse effects due to immune activation.
Demonstrated efficacy across various solid tumors expressing PD-L1 or with high tumor mutational burden.
Lack of hepatic metabolism minimizes drug-drug interactions and increases tolerability.
Long half-life allowing sustained immune checkpoint inhibition and convenient dosing schedules.

Therapeutic Or Clinical Uses

Treatment of metastatic or advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression without EGFR or ALK mutations.
First-line treatment of metastatic non-squamous NSCLC in combination with bevacizumab, paclitaxel, and carboplatin.
Treatment of extensive-stage small cell lung cancer (ES-SCLC) in combination with carboplatin and etoposide.
Treatment of unresectable or metastatic hepatocellular carcinoma (HCC) in combination with bevacizumab in patients not previously treated systemically.
Treatment of unresectable or metastatic BRAF V600 mutation-positive melanoma in combination with cobimetinib and vemurafenib.
Treatment of unresectable or metastatic alveolar soft part sarcoma (ASPS) in adults and pediatric patients aged 2 years and older.
Adjuvant therapy post-surgical resection and platinum chemotherapy for stage II to IIIA NSCLC with PD-L1 positive tumors to prevent cancer recurrence.
Treatment of metastatic NSCLC after progression on platinum-containing chemotherapy.
Treatment option for patients who have failed prior approved therapies targeting EGFR or ALK aberrations if applicable.
Utilized when conventional chemotherapy is contraindicated or has failed, leveraging immune system activation.

Side Or Adverse Effects

Immune-mediated pneumonitis causing cough, shortness of breath, and chest pain.
Hepatotoxicity characterized by elevated liver enzymes, jaundice, dark urine, and abdominal pain.
Gastrointestinal toxicities including severe diarrhea, colitis, nausea, vomiting, and abdominal pain.
Endocrinopathies such as hypothyroidism, hyperthyroidism, adrenal insufficiency, pituitary inflammation, and diabetes mellitus.
Skin reactions including rash, pruritus, and severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome).
Infusion-related reactions manifesting as fever, chills, flushing, hypotension, and respiratory distress during or shortly after administration.
Fatigue, weakness, and fever common as systemic immune activation effects.
Musculoskeletal pain, including arthralgia, myalgia, and bone pain.
Hematologic abnormalities such as anemia, leukopenia, thrombocytopenia, increasing infection risk.
Neurologic toxicities such as neuropathy, headache, dizziness, muscle weakness, and rare cases of Guillain-Barré syndrome.
Renal adverse events including nephritis and potential renal function impairment.
Hypersensitivity reactions, including rare anaphylaxis.
Potential for endocrinological hormonal imbalances causing mood changes, weight fluctuations, increased thirst, and urination.
Hair loss (alopecia) most commonly observed in combination regimens.
Edema and peripheral swelling in arms or legs.

Precautions

Careful patient selection including assessment for autoimmune diseases such as lupus, ulcerative colitis, or Crohn’s disease due to risk of immune exacerbation.
Monitor for and manage immune-related adverse effects promptly to avoid severe complications.
Assess liver function before and during treatment especially in patients with pre-existing liver disease.
Screen for infections before and during therapy as immune modulation may obscure signs.
Evaluate respiratory status frequently to detect early signs of pneumonitis.
Avoid use during pregnancy due to potential fetal harm; enforce effective contraception during and for 5 months post-treatment.
Do not breastfeed during treatment and for 5 months after last dose to avoid exposure to the infant.
Monitor for neurologic symptoms that may suggest immune-mediated neuropathies.
Use caution when combining with other immunosuppressive or immune-modulating therapies.
Test for PD-L1 expression and relevant tumor mutations (EGFR, ALK, BRAF) prior to treatment initiation to optimize patient selection.
Inform patients about the possibility of infusion-related reactions and educate on symptom recognition.
Consider delaying or discontinuing therapy in the case of severe adverse reactions.
Ensure vaccination status is adequate; live vaccines are contraindicated during treatment.
Pre-medicate or provide supportive care for infusion-related reactions per institutional protocols.
Facilitate regular clinical and laboratory monitoring for early detection of toxicity.

Warnings

Potential for fatal or life-threatening immune-mediated adverse reactions affecting lungs, liver, GI tract, endocrine glands, and skin.
May cause severe or fatal pneumonitis; immediate evaluation and treatment recommended if respiratory symptoms develop.
Risk of fatal hepatitis; monitor liver function tests prior to and during therapy.
Immune-mediated colitis can result in bowel perforation or severe diarrhea requiring prompt intervention.
Endocrine dysfunctions may be irreversible; routine hormonal evaluation and prompt management necessary.
Do not use in patients with a known hypersensitivity to atezolizumab or any excipients.
Use during pregnancy can result in fetal harm; contraindicated in pregnant women.
Concomitant use with immunosuppressive agents may diminish therapeutic efficacy.
Serious infusion-related reactions requiring interruption or permanent discontinuation have been reported.
Potential for delayed immune-related adverse events occurring even after treatment discontinuation.
Risk of infections may increase due to immune system modulation.
Close monitoring required when switching from or to other immunotherapies.
Patients who have received stem cell or organ transplants require careful consideration due to risk of graft rejection.
Risk of exacerbation of pre-existing autoimmune or inflammatory disorders.
May cause fetal harm; the need for contraception extends for at least 5 months after last dose.

Contraindication

Known hypersensitivity or allergy to atezolizumab or any component of the formulation.
Pregnancy due to potential teratogenicity and fetal harm.
Use in breastfeeding mothers unless discontinuation of breastfeeding.
Patients with active or uncontrolled autoimmune diseases without careful risk-benefit assessment.
Concurrent participation in other investigational anti-cancer drug trials unless approved by the physician.
Severe infusion reactions to atezolizumab requiring permanent discontinuation.
History of severe hypersensitivity reactions to monoclonal antibodies targeting PD-1 or PD-L1.
Unstable or severe comorbidities contraindicating immunotherapy, as judged by treating physician.
Use in children under 2 years of age for alveolar soft part sarcoma, safety and efficacy unknown.
Uncontrolled systemic infections at the time of planned therapy initiation.
Patients who have not received appropriate prior therapies for tumors harboring EGFR or ALK mutations when indicated.
Known macrophage activation syndrome or active severe immune cytopenias.
Concurrent use of live vaccines during treatment.
Known hypersensitivity to other components of combination therapy regimens with atezolizumab.

Drug Interactions

No significant pharmacokinetic interactions expected due to catabolism by proteolytic enzymes rather than liver metabolism.
Potential for immune-related adverse effect augmentation when combined with other immunotherapies or immune-modulators.
Concomitant corticosteroids or immunosuppressants may reduce atezolizumab efficacy by dampening immune activation.
Atezolizumab may affect pharmacodynamics of chemotherapeutic agents administered simultaneously, requiring treatment timing optimization.
Possible enhanced toxicity when combined with VEGF inhibitors such as bevacizumab; monitor for overlapping adverse effects.
Interactions reported with paclitaxel and carboplatin in combination regimens, though primarily due to chemotherapy effects rather than atezolizumab.
No CYP450 enzyme induction or inhibition, limiting interactions via hepatic metabolism pathways.
Use caution when administering live vaccines, as immune checkpoint inhibition may alter vaccine responses.
Immunosuppressive agents including methotrexate, TNF-alpha inhibitors may interfere with atezolizumab efficacy.
Potential pharmacodynamic interactions with BRAF and MEK inhibitors (vemurafenib and cobimetinib) when used in combination for melanoma.
Unknown interactions with herbal supplements or vitamins affecting immune function; discuss all concurrent agents with healthcare provider.
Concurrent antiviral, antifungal, or antibiotic therapies generally safe but monitor for immune status and infection control.
No known significant interactions with analgesic or antiemetic agents commonly used in oncology supportive care.
May interact with anticoagulants indirectly via bleeding risks related to immune-mediated adverse events.
Potential interaction with stem cell transplant procedures given immune modulatory mechanism.

Preparations Of The Drug

Tecentriq is supplied as a sterile, preservative-free, single-dose vial containing atezolizumab solution for intravenous infusion.
Available vial strengths are 1200 mg in 20 mL (60 mg/mL) and 840 mg in 14 mL (60 mg/mL).
Formulated as a clear to slightly opalescent, colorless to pale yellow solution.
Requires dilution prior to administration with 0.9% Sodium Chloride Injection for intravenous infusion.
Should be administered by slow IV infusion over 60 minutes for the initial dose; subsequent infusion times may be reduced to 30 minutes if tolerated.
Not intended for bolus injection or rapid infusion due to risk of infusion-related reactions.
Storage requirements include refrigeration between 2°C to 8°C (36°F to 46°F) and protection from light.
Once diluted, the infusion solution should be used promptly or stored refrigerated and administered within recommended time frames to maintain stability.
A subcutaneous formulation (Tecentriq Hybreza) is available which combines atezolizumab and hyaluronidase but is administered differently and not detailed in this summary.
The product is preservative-free; aseptic technique is essential for preparation and administration.
Does not require any special handling beyond standard monoclonal antibody protocols; use aseptic technique to avoid contamination.
Patient education materials emphasize following infusion-related precautions, recognizing adverse reactions, and the need for adherence to scheduled treatments.
Typically supplied by specialty pharmacy or hospital pharmacy with oncology drug dispensing.
Genentech, the manufacturer, provides financial assistance programs to support patient access to Tecentriq.
Disposal of unused drug and materials should comply with institutional biohazard waste policies.